
Kevin Costa, PhD
About Me
Research in the Costa Laboratory is focused on understanding how biomechanical factors impact cardiovascular cell and tissue function in healthy and diseased states. Sophisticated computational modeling is combined with state-of-the-art experimental methods to attack this challenging multi-scale problem. Atomic force microscopy (AFM) is used to probe the micro-scale viscoelastic mechanobiological response of living cells and tissue samples. Novel engineered tissues and organoids are created for investigating mechanisms of cardiovascular remodeling, injury, repair, and regeneration. These living model systems allow unprecedented control of tissue composition, structure, and geometry combined with advantages of long-term viability and high-throughput therapeutic screening capability. An emphasis on human-derived cell sources helps to ensure clinically translatable outcomes from modulating patient-specific cardiovascular niche environments, ultimately helping to transform the fields of tissue engineering, cardiology, and personalized regenerative medicine.
Dr. Costa has received research funding from the Whitaker Foundation, the National Science Foundation (NSF) and the National Institutes of Health (NIH; NHLBI, NIBIB, and NIGMS). He was a recipient of the prestigious Faculty Early Career Development (CAREER) Award from the NSF, and has served on the Editorial Boards for Biophysical Journal and the new journal Molecular and Cellular Bioengineering.
Language
English
Position
ASSOCIATE PROFESSOR | Medicine, Cardiology
Research Topics
Biomechanics/Bioengineering, Cardiovascular, Cellular Differentiation, Computer Simulation, Cytoskeleton, Mathematical Modeling of Biomedical Systems, Muscle Cells, Regeneration, Stem Cells, Tissue Engineering, Wound Healing
Multi-Disciplinary Training Areas
Artificial Intelligence and Emerging Technologies in Medicine [AIET], Development Regeneration and Stem Cells [DRS], Disease Mechanisms and Therapeutics (DMT)
Video
Education
MS, Boston University
PhD, University of California, San Diego
Research
Publications
Selected Publications
- Rationale and design of MUSIC-HFpEF: a phase 1b, pilot trial evaluating the safety and pharmacodynamic effects of AAV1.SERCA2A in heart failure with preserved ejection fraction. Marat Fudim, Satyam Sarma, James P. MacNamara, Deborah D. Ascheim, Veraprapas Kittipibul, Katheryn Doukellis, Andy Dhimitri, Robert Fitzhugh, Niharika Kamat, Kevin D. Costa, Jeffrey Rudy, Janet Guerrero, Camie Chan, Ronald A. Li, Anthony A. Bavry, Manesh R. Patel, Justin L. Grodin, Benjamin D. Levine, Roger J. Hajjar. Heart Failure Reviews
- Invasion of glioma cells through confined space requires membrane tension regulation and mechano-electrical coupling via Plexin-B2. Chrystian Junqueira Alves, Theodore Hannah, Sita Sadia, Christy Kolsteeg, Angela Dixon, Robert J. Wiener, Ha Nguyen, Murray J. Tipping, Júlia Silva Ladeira, Paula Fernandes da Costa Franklin, Nathália de Paula Dutra de Nigro, Rodrigo Alves Dias, Priscila V. Zabala Capriles, José P. Rodrigues Furtado de Mendonça, Paul A. Slesinger, Kevin D. Costa, Hongyan Zou, Roland H. Friedel. Nature Communications
- Design and implementation of a Targeted HealthcaRe InnoVation & Entrepreneurship (THRIVE) fellowship program. Ian C. Odland, Joseph Borrello, Layla Fattah, Tyree D. Williams, Kevin D. Costa, David Putrino, Brian Nickerson, Holly Oemke, Turner Baker, James McKay, Dov B. Shamir, Juan Quijano, Janice Gabrilove. PLoS ONE
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Costa during 2025 and/or 2026. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Board Service
- Novoheart US Corp
Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)
- Medera Biopharmaceutical
Founder/Co-Founder/Partner
- Novoheart International Ltd
Mount Sinai’s faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.